Well-known pharmaceutical companies heavy varieties were approved for listing, is the first of its kind over the review

Pharmaceutical Network Enterprise News" Recently, Dongsun Pharmaceutical sinboard announced that the company from Guangdong East Sunshine Pharmaceutical Co., Ltdto buy the product Esomeprazole magnesium intestinal capsule (20mg and 40mg) approved by the State Drug Administration and approved for listing, followed by a supplementary application, the product's listing license holder will be changed to the company or the company's holding subsidiaryit is reported that Esoxomeprazole is a proton pump inhibitor acid suppressor drug, mainly used to treat reflux esophageal itisand and other stomach acid-related diseases, first developed by Sweden's AstraZeneca AB company, was approved to enter China in 2007, in 2019 Astrazeneca was qualified for local productionEast Sunshine Pharmaceuticals said in a statement, compared with other categories of proton pump inhibitor drugs, Esomeprazole has a faster effect, acid suppression effect is more durable and so onAccording to Ames China market data, sales of Esaumeprazole in 2019 were approximately $490 million, representing a COMPOUND growth rate of 24% over the past three years, accounting for 19% of total sales of proton pump inhibitorsAccording to the data of RiceNet, sales of Aisomeprazole in China's public medical institutions in 2019 amounted to 5.375 billion yuan, which has passed the 5 billion yuan mark, up 15.71 percent year-on-yearfrom the market pattern, in 2019 China's public medical institutions terminal, Esabiomeprazole sales of the top three manufacturers are AstraZeneca, Zhengda Tianqing and Chongqing Laimei PharmaceuticalsAmong them, the sales of AstraZeneca, a former research firm, have gradually declined in recent years, with market share falling from 98.66 percent in 2015 to 63.23 percent in 2019, while Zhengda's market share has increased year by year, exceeding 20 percent in 2019it is understood that the current domestic dosage form of Esomeprazole mainly includes injection with esofraprazole sodium, esomeprazole magnesium intestinal tablets, esomeprazole intestinal capsulesFrom the National Drug Administration database query learned that the injection of esmoprazole sodium domestic approval up to 34, holding approval of pharmaceutical enterprises including AstraZeneca, Hesse, Yangzijiang, Shandong Luoxin, Lepu, Zhengdaqing, Qilu, Yichang Dong Sunshine Yangtze River Pharmaceutical sequining and other well-known pharmaceutical companies;and esmoprazole intestinal capsules have only two domestic approvals, held by Chongqing Lemmy PharmaceuticalsIn addition, Insight database shows that the current domestic in accordance with the new registration classification to declare Esmoprazole intestinal capsules of enterprises are also Zhengda Tianqing, stone pharmaceutical groupit is worth mentioning that the East Sunshine Pharmaceuticals' Esofraprazine enzymatic intestinal capsule was approved for listing, in accordance with the new registration classification was approved as through the consistency evaluation, is the first domestic company through the consistency evaluation of the enterprise, the future market space is largerDongsun Pharmaceuticals said that the approved listing of the product further enriched the group's product line, will also provide patients with more high-quality dual-quality drug optionsAt the same time, the Group will continue to promote the process of new product development pipeline, committed to supplementing the unmet clinical drug demand the author learned that the recent East Sunshine Pharmaceutical Products approved to market the news is more frequent Not long ago, Dongsun Pharmaceuticalalso also announced that the company from Guangdong Dongsun Pharmaceuticals to buy the product Entikave tablets (0.5 mg and 1 mg) has been approved by the State Drug Administration and approved for listing East Sunshine Drug to join the 7 billion varieties of the market competition, will be in the field of the next city.